Table 3.
Number of diagnoses, age at first primary neoplasm (FPN) for all sampled cases and controls (including backup controls), age at subsequent primary neoplasms (SPN) and latency between first and subsequent primary neoplasm in years for all sampled cases, by subsequent neoplasm*
| Subsequent neoplasm | N | Cases | Controls a,b | Total | |||
|---|---|---|---|---|---|---|---|
| Age in years at FPN diagnosis | Age in years at SPN diagnosis | Latency (y) to SPN | N | Age in years at FPN diagnosis | |||
| Mean (Min–Max) | Mean (Min – Max) | Mean (Min–Max) | Mean (Min–Max) | ||||
| Lymphoid leukemia | 47 | 6.2 (0–14) | 11.6 (2–24) | 5.5 (0.6–18.1) | 188 | 6.2 (0–14) | 235 |
| Acute myeloid leukemia | 203 | 6.4 (0–14) | 10.8 (1–29) | 4.4 (0.5–22.2) | 812 | 6.4 (0–14) | 1015 |
| Other leukemia | 6 | 10.8 (5–14) | 14.8 (9–19) | 3.9 (1.6–5.9) | 24 | 10.9 (5–14) | 30 |
| Hodgkin ‘s disease | 21 | 5.7 (0–14) | 14.1 (4–31) | 8.3 (1.6–20.2) | 84 | 5.7 (0–14) | 105 |
| Non-Hodgkin ‘s disease | 62 | 6.6 (0–14) | 14.2 (2–39) | 7.6 (0.7–29.1) | 248 | 6.6 (0–14) | 310 |
| Other lymphomas | 8 | 5.0 (0–11) | 9.8 (3–19) | 4.6 (0.7–11.3) | 32 | 5.0 (0–11) | 40 |
| Non-malignant CNS-tumors | 147 | 5.8 (0–14) | 23.2 (5–42) | 17.4 (0.5–30.4) | 588 | 5.8 (0–14) | 735 |
| Malignant CNS-tumors | 134 | 5.3 (0–14) | 13.4 (2–32) | 8.1 (1.6–28.1) | 536 | 5.3 (0–14) | 670 |
| Neuroblastomas | 8 | 2.0 (0–10) | 6.4 (2–17) | 4.4 (1.1–14.0) | 32 | 2.0 (0–10) | 40 |
| Retinoblastomas | 3 | ** | ** | ** | 12 | 3.0 (1–6) | 15 |
| Renal tumors | 14 | 4.3 (0–13) | 14.1 (1–34) | 9.7 (0.6–25.1) | 56 | 4.3 (0–14) | 70 |
| Liver tumors | 7 | 4.9 (2–9) | 20.0 (4–37) | 15.0 (1.7–32.3) | 28 | 5.0 (2–9) | 35 |
| Bone tumors | 66 | 4.3 (0–14) | 13.8 (4–29) | 9.5 (2.3–28.7) | 264 | 4.4 (0–14) | 330 |
| Soft tissue sarcomas | 62 | 5.1 (0–14) | 16.0 (2–40) | 11.0 (1.0–31.9) | 248 | 5.1 (0–14) | 310 |
| Germ cell tumors | 13 | 7.0 (0–14) | 20.7 (10–38) | 13.7 (2.8–24.6) | 52 | 7.0 (0–14) | 65 |
| Thyroid carcinomas | 145 | 6.9 (0–14) | 21.1 (6–41) | 14.2 (2.3–33.1) | 580 | 6.9 (0–14) | 725 |
| Skin tumors incl. Malignant Melanoma | 153 | 7.3 (0–14) | 26.4 (5–43) | 19.1 (1.5–32.8) | 612 | 7.3 (0–14) | 765 |
| Other tumors | 145 | 9.3 (0–14) | 26.7 (4–46) | 17.4 (0.6–32.1) | 580 | 9.4 (0–14) | 725 |
| Total | 1244 | 6.5 (0–14) | 18.4 (1–46) | 11.9 (0.5–33.1) | 4976 | 6.5 (0–14) | 6220 |
CNS central nervous system, SPN subsequent primary neoplasm, y years, N number of cases
*Inclusion criteria for cases and controls: age at diagnosis of first neoplasm below 15, year of diagnosis of first neoplasm between 1980 and 2014, resident in Germany at the time of both the diagnosis of the first and second neoplasm, minimum latency between first and subsequent neoplasm: 0.5 years **No results given as the number of patients was below 5
aSome patients were selected as case and as control for a different case (whose SPN occurred later in terms of age at diagnosis). Such individuals can account for multiple diagnosed tumors in this table, which have occurred at different periods in their lives
bResults refer to the subsequent neoplasm of the respective case